FDA Registered vs. FDA Approved: What the Difference Means for Your QMS

TLDR

"FDA registered" and "FDA approved" describe two entirely different things. FDA registration is a facility-level requirement: manufacturers, importers, and other establishments must register annually with the FDA to notify the agency of their existence and operations. FDA approval, clearance, or authorization is a product-level requirement: it confirms the FDA has reviewed a specific product and found it safe and effective for its intended use. The confusion between these terms creates real legal risk for regulated companies, and for quality teams in medical devices and pharma, the distinction directly shapes how you build and sustain your QMS.

What Does "FDA Registered" Actually Mean?

An FDA registered facility is one that has submitted establishment registration to the FDA as required by federal law. For medical device establishments, this obligation falls under 21 CFR Part 807. For drug and biologic establishments, it falls under 21 CFR Part 207. Both regulations require annual registration and product listing by owners or operators of facilities involved in producing or distributing FDA-regulated products intended for use in the United States.

FDA registration notifies the FDA of your facility's location, the types of activities performed there, and the products you make or distribute. It gives the FDA a mechanism to schedule inspections, track establishments, and enforce good manufacturing practice requirements. It does not signify that the FDA has reviewed or endorsed your product.

The FDA states this directly:

"Owners or operators of places of business (also called establishments or facilities) that are involved in the production and distribution of medical devices intended for use in the United States are generally required to register annually with the FDA. When a device establishment registers with the FDA, it does not mean that FDA has approved that establishment or its devices." (FDA.gov)

FDA registration is an administrative notification requirement. The government maintains a directory of who makes and distributes regulated products through this process. Product safety and effectiveness are evaluated separately through premarket review pathways.

FDA Registered vs. FDA Approved: The Core Distinction

The core distinction comes down to what is being described. FDA registration applies to establishments (facilities). FDA approval, clearance, or authorization applies to products.

Establishment Registration (Facility Level)

An FDA registered establishment has fulfilled its obligation to notify the FDA of its operations. This covers:

Registration does not require the FDA to inspect your facility before you operate, and it does not require the FDA to review your product. Registration is a notification to the FDA, a required administrative step under federal law.

Product Authorization (Product Level)

Before a regulated product can be legally sold in the United States, it must receive authorization through a premarket review pathway. The applicable pathway depends on the product type and risk classification:

A facility can be FDA registered while distributing a product that has never completed premarket review. That combination is illegal for most product classes, but registration itself does not reveal whether a product is lawfully on the market.

What "FDA Registered" Does Not Tell You

FDA registered is one of the most commonly misused phrases in regulated product marketing. Here is what the phrase does not communicate:

Companies that present FDA registration as equivalent to product approval risk misbranding enforcement under the Federal Food, Drug, and Cosmetic Act. The FDA has flagged this as a consumer protection issue, particularly for products sold directly to the public. (FDA.gov)

Who Must Register with the FDA?

Medical Device Establishments: 21 CFR Part 807

Under 21 CFR Part 807, the following establishment types must register with the FDA annually and list the devices they manufacture or distribute:

Registration is submitted through the FDA's Unified Registration and Listing System (FURLS). For FY 2026, an annual establishment registration fee applies to most device establishments. The FDA offers a fee waiver for qualifying small businesses through its Small Business Determination Program. (FDA.gov)

Drug and Biologic Establishments: 21 CFR Part 207

Under 21 CFR Part 207, domestic drug manufacturers must register within 5 calendar days of beginning manufacturing operations. Foreign manufacturers must register before exporting drugs to the United States. Annual renewal is required, and the registration must include a drug listing that identifies each product associated with the facility.

Both device and drug registrations require a corresponding product listing, a separate step that ties specific products to the registered establishment.

Device Listing: The Companion Requirement

Device listing under 21 CFR Part 807 runs alongside facility registration. When a device establishment registers, it must identify each device manufactured at or distributed from that location, along with:

This is where registration and product authorization intersect. Device listing forces establishments to specify the regulatory pathway for each product. If a device lacks a valid premarket submission or an appropriate exemption, listing makes that gap visible to the FDA directly.

QMS Requirements for Registration Readiness

Registration is the administrative entry point. What follows registration is where quality management becomes operationally critical.

Once a facility is FDA registered, it is subject to FDA inspection at any time. For medical device manufacturers, inspectors evaluate compliance with the Quality Management System Regulation (QMSR), which became effective February 2, 2026. The QMSR amends 21 CFR Part 820 to incorporate ISO 13485:2016 by reference, harmonizing FDA requirements with international quality standards used by regulatory authorities globally. (FDA.gov)

For pharmaceutical manufacturers, current Good Manufacturing Practice (cGMP) requirements under 21 CFR Parts 210 and 211 govern production controls, documentation, laboratory testing, and records management.

Registration readiness means your QMS is inspection-ready before the FDA arrives. The core areas inspectors assess include:

Document Control

Your QMS must maintain controlled, approved procedures for all manufacturing and quality processes. Procedures must be version-controlled, approved before use, and accessible to the personnel who need them. Change management workflows must document who authorized each revision and when.

CAPA Management

Deviation CAPA processes are central to both QMSR and cGMP compliance. FDA inspectors look for documented evidence that your organization identifies nonconformances, investigates root causes, implements corrections, and verifies effectiveness. A CAPA system that exists on paper but does not function in practice is a primary source of FDA Form 483 observations.

Complaints and Adverse Events

Product complaints and adverse events must be captured, investigated, and evaluated for reportability. Medical device manufacturers must meet Medical Device Reporting (MDR) requirements. Pharmaceutical manufacturers must comply with adverse drug experience reporting obligations. Both require documented investigation processes tied to the QMS.

Internal Audits

Planned internal audits verify that your QMS functions as documented, not just as written. ISO 13485:2016 and the QMSR require scheduled internal audits with documented audit findings and corrective actions. Audit records also serve as evidence during FDA inspections that your organization conducts ongoing self-assessment.

Electronic Records and Audit Trails

If your QMS or manufacturing systems use electronic records, 21 CFR Part 11 applies. Part 11 requires validated systems, electronic signatures with appropriate controls, and a secure, tamper-evident audit trail for all regulated records. This requirement applies to quality records used to demonstrate compliance with FDA requirements.

Why the Distinction Matters for Your QMS Strategy

The difference between FDA registration and FDA approval has a direct impact on QMS planning and resource allocation.

Registration is your entry point to FDA oversight. The moment your establishment is registered, FDA inspection authority activates. A QMS that is not inspection-ready from day one of registration creates immediate compliance exposure, regardless of where you are in your product development cycle.

Product authorization requires documented evidence that your QMS produces reliable, traceable quality data. Design controls, risk management records, test results, and deviation histories all flow from a QMS that functions in practice. A submission that references processes not supported by operational QMS records is a significant liability during review.

Companies that treat registration as a one-time administrative task and view product authorization as a separate exercise frequently encounter FDA Form 483 observations during inspections, findings that could often have been addressed before the FDA arrived.

A unified QMS approach, one that keeps registration-maintenance processes (document control, CAPA, complaints, internal audits) aligned with product development requirements (design controls, risk management, clinical data), is the foundation of sustainable regulatory compliance.

How QMS Software Supports Both Registration and Product Authorization

QMS software built for regulated industries removes the operational gap between facility-level compliance and product-level compliance.

Cloudtheapp is a QMSR-compliant platform, validated to FDA Computer System Validation guidelines and 21 CFR Part 11. Its no-code, AI-powered platform includes dedicated applications for Documents, CAPA, Complaints, and Audits, covering the core processes FDA inspectors evaluate during establishment inspections.

The Documents app enforces controlled, version-managed procedures with full approval workflows. The CAPA app tracks nonconformances from detection through root cause analysis to verified closure. The Complaints app captures product complaints and links them to adverse event investigation workflows. The Audits app schedules, executes, and closes internal and supplier audits with documented audit findings and corrective actions.

Because Cloudtheapp validates each platform update against FDA Computer System Validation guidelines, quality teams maintain registration readiness continuously without launching separate validation projects every time the platform evolves.

For organizations managing a registered facility alongside an active product pipeline, Cloudtheapp connects registration-maintenance workflows to premarket readiness in a single, integrated platform.

Request a Demo at cloudtheapp.com

Conclusion

FDA registered and FDA approved describe two different things operating at two different levels. Registration tells the FDA where you are and what activities you perform. Approval, clearance, or authorization confirms that a specific product has been reviewed and found safe and effective.

The legal consequences of the distinction are real: misbranding risk for companies that misuse the phrase in marketing, and inspection exposure for quality teams that underestimate what registration triggers in terms of ongoing QMS obligations.

A well-structured QMS is the operational bridge between registration and authorization. It keeps your facility inspection-ready from the moment you register, and it produces the documented evidence that premarket authorization pathways require.

Sources: